Corbus Plans CRB-913 Phase 1b Obesity Trial Data Presentation at Obesity Week 2026

PUBT · 2d ago
Corbus Plans CRB-913 Phase 1b Obesity Trial Data Presentation at Obesity Week 2026
  • Corbus Pharmaceuticals will present CRB-913 Phase 1b CANYON-1 study data at Obesity Week on November 15, 2026, in National Harbor, Maryland.
  • The presentation will cover efficacy, safety and tolerability of CRB-913, an oral drug candidate for obesity.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corbus Pharmaceuticals Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610220800PRIMZONEFULLFEED9850803) on October 22, 2026, and is solely responsible for the information contained therein.